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AbstrAct:
	 Tumor	necrosis	factor-α	(TNF-α)	has	been	discussed	as	a	potential	anticancer	
agent for many years, however initial enthusiasm about its clinical use as a systemic 
agent	 was	 curbed	 due	 to	 significant	 toxicities	 and	 lack	 of	 efficacy.	 Combination	 of	 TNF-α	
with	chemotherapy	in	the	setting	of	hyperthermic	isolated	limb	perfusion	(ILP)	has	
provided new insights into a potential therapeutic role of this agent. The therapeutic 
benefit	from	TNF-α	in	ILP	is	thought	to	be	not	only	due	to	its	direct	anti-proliferative	
effect, but also due to its ability to increase penetration of the chemotherapeutic 
agents	into	the	tumor	tissue.	New	concepts	for	the	use	of	TNF-α	as	a	facilitator	rather	
than	as	a	direct	actor	are	currently	being	explored	with	the	goal	to	exploit	the	ability	
of	this	agent	to	increase	drug	delivery	and	to	simultaneously	reduce	systemic	toxicity.	
  This review article provides a comprehensive overview on the published 
previous	 experience	 with	 systemic	 TNF-α.	 Data	 from	 18	 phase	 I	 and	 10	
phase	 II	 single	 agent	 as	 well	 as	 18	 combination	 therapy	 studies	 illustrate	
previously used treatment and dose schedules, response data as well as the 
most prominently observed adverse effects. Also discussed, based on recent 
preclinical	 data,	 is	 a	 potential	 future	 role	 of	 systemic	 TNF-α	 in	 combination	
with	 liposomal	 chemotherapy	 to	 facilitate	 increased	 drug	 uptake	 into	 tumors.	
IntroductIon
TNF-α was discovered in 1975 and subsequently 
cloned in 1984 [1, 2] and has been the focus of considerable 
interest  as  an  anticancer  agent.  Initial  enthusiasm  for 
TNF-α as a systemic therapeutic agent stemmed from the 
observation that it could induce hemorrhagic necrosis in 
the  tumors  of  bacillus  Calmette-Guérin  (BCG)-primed 
and  endotoxin  treated  mice  [1].  Recombinant  human 
TNF-α (rhTNF-α) has been tested as a systemic treatment 
in several phase I and phase II clinical trials. These trials, 
conducted in the 1980s and 1990s, used TNF-α as both 
a single agent and in combination with other cytokines 
or  chemotherapeutics.  However,  the  initial  enthusiasm 
for the development of TNF-α as a systemic treatment 
has waned in the face of significant toxicities and a lack 
of evidence for therapeutic benefit. Nevertheless, these 
studies have provided valuable data regarding the toxicity 
profile  and  pharmacological  properties  of  systemically 
delivered TNF-α. More encouraging is the current clinical 
use of combination TNF-α with chemotherapeutic agents 
in  the  setting  of  hyperthermic  isolated  limb  perfusion 
in  limb-threatening  soft  tissue  sarcomas  and  in-transit 
melanoma [3]. Here we review the phase I and phase II 
clinical  trials  of  systemic  use  of TNF-α,  the  toxicities 
and responses observed, and highlight recent scientific 
advances  that  hint  at  reduced  systemic  toxicities  and 
augmentation of the antitumor responses seen with this 
agent. Specifically, the recently identified vascular effects 
of TNF-α that lead to a targeted intra-tumoral enrichment 
of liposomes and macromolecules through an enhanced-
enhanced permeability and retention effect (E2PR) [4-6].
bIology of tnf-α
TNF-α  is  a  23  kilodalton  (kDa)  type  II 
transmembrane protein arranged in stable homotrimers. 
A 51 kDa soluble homotrimeric cytokine is derived from Oncotarget 2011; 2:  739 - 751 740 www.impactjournals.com/oncotarget
the transmembrane form via proteolytic cleavage by the 
metalloprotease TNF-α converting enzyme (TACE) [7]. 
TNF-α is primarily produced by macrophages, but also by 
a variety of other cells, including NK cells, T lymphocytes, 
smooth muscle cells, fibroblasts and others [8]. Release 
of TNF-α occurs in response to inflammatory stimuli and 
cytokines  including  peptidoglycan,  lipopolysaccharide 
and  other  bacterial  components  [9].  Two  receptors 
exist  for  TNF-α:  1).  Tumor  necrosis  factor  receptor  1 
(TNFR1), which preferentially binds soluble TNF-α and 
is found almost ubiquitously on the surface of cells, and 
2). Tumor necrosis factor receptor 2 (TNFR2), which is 
found on cells of the hematopoietic lineage and which has 
specificity for the transmembrane form of TNF-α [10]. 
The resulting biological effect of TNF-α binding to its 
receptor is depending on the type of receptor activated and 
the cellular state during activation. Stimulation of TNFR1 
activates  downstream  inflammatory  mediators  through 
AP1,  MAPK  and  NF-kB  pathways  [11].  The  balance 
of activation of these pathways by TNF-α is critical in 
determining whether a cell undergoes apoptosis as a late 
stage event in TNF-α stimulation. For instance, in acute 
myeloid  leukemia  (AML),  NF-kB  dependent  induction 
of HO-1 underlies resistance to TNF-α induced apoptosis 
[12]. Similarly, inhibition of NF-kB with concurrent TNF-α 
stimulation  results  in  caspase  activation  and  apoptosis 
[13].  Conversely,  the  biological  role  and  downstream 
effects of TNFR2 stimulation are more poorly understood. 
TNFR2  can  be  up-regulated  by  cytokine  stimulation 
and also mediate a variety of downstream inflammatory 
mediators [14].
PreclInIcAl evIdence for tnf-α 
As An AntIcAncer Agent
After  the  initial  observation  that  TNF-α  induced 
hemorrhagic necrosis of tumors in mice treated with BCG 
and endotoxin [1], the potential of TNF-α as a therapeutic 
agent was intensely studied in in vitro and in vivo studies. 
These studies highlighted the possible role of TNF-α as an 
anticancer agent and galvanized support for the numerous 
phase I and phase II studies that followed. 
In vitro  studies  demonstrated  that  TNF-α  had  a 
growth  inhibitory  effect  on  SV40-tranformed  human 
mammary epithelia cells and a cytotoxic effect on breast 
cancer  cell  lines.  Interestingly,  there  was  no  effect  on 
normal human mammary epithelial cells [15]. Similarly, 
TNF-α  showed  a  cytostatic  effect  on  hepatoma  cells 
while having little effect on non-tumorigenic liver cells 
[16]. Intriguingly, Sugarman and colleagues showed that 
the cytostatic and cytotoxic effects of TNF-α were cell 
line specific, with only a proportion of tumor cell lines 
responding to TNF-α [17]. Comparison of the cytostatic 
and cytotoxic effect of TNF-α against a wide range of 
tumor types demonstrated that approximately a quarter of 
tumors (28%) are sensitive to the effects of TNF-α and 
that  this  sensitivity  was  greater  in  colorectal  and  lung 
cancers [18]. In vivo, TNF-α has shown activity against 
a wide variety of murine tumor types and human tumor 
xenografts [19-21]. Taken together, the in vitro and in vivo 
data were suggestive that TNF-α had the potential to be 
highly specific anti-cancer therapy, with activity against a 
number of tumor types. 
Preclinical  evidence  also  suggested  a  synergistic 
effect  of  TNF-α  with  a  variety  of  chemotherapeutics 
in vitro and in vivo. TNF-α has been shown to enhance 
the  cytotoxicity  of  DNA  topoisomerase  inhibitors 
actinomycin D, adriamycin, and etoposide against murine 
bladder tumor cell line (MBT-2) in in vitro and in vivo 
models  [22].  The  enhancing  effect  of  TNF-α  was  not 
observed with other cytotoxic agents, such as: bleomycin, 
hydroxyurea,  cisplatin,  mitomycin  C,  vincristine  and 
vinblastine. The timing of TNF-α treatment in relation to 
chemotherapy seems important with studies suggesting 
that the optimal time for TNF-α therapy is 48 hours prior 
to initiation of chemotherapy [23]. Interestingly, there are 
likely two mechanisms that underlie the importance of 
timing in regards to TNF-α treatment. Firstly, inhibitors of 
transcription, such as actinomycin D and flavopiridol, are 
used before or at the time of TNF-α treatment and block 
NF-kB pathway activation, sensitizing cells to the effects 
of TNF-α [24]. Secondly, inhibitors of topoisomerase II 
can be given at the time of, or after TNF-α and increase 
the  sensitivity  of  TNF-α  resistant  cancer  cell  lines  to 
TNF-α [25]. 
TNF-α also demonstrated enhanced antitumor effects 
in vitro when used in combination with other cytokines 
[26]. Induction of TNF-α receptors rather than an increased 
affinity of already present receptors explained the effect 
of IFN-γ on TNF-α binding [26, 27]. Similarly, in vitro 
and in vivo studies using the TNF-α resistant melanoma 
cell  line  B16BL6  demonstrated  that  IFN-γ  sensitizes 
cancer cells to the effects of TNF-α, inducing necrosis 
and  tumor  response,  which  were  previously  absent 
[28].  Later,  investigators  showed  that  TNF-α  induced 
synergistic  growth  inhibition  against  pancreatic  cancer 
cell lines when combined with interferon alpha (IFN-α) 
and IFN-γ [29]. TNF-α and IFN-γ act against many other 
cancer cell lines as well. Orita et al. [30] tested TNF-α 
and IFN-γ on 23 cell lines in vitro and demonstrated that 
the combination acts synergistically, showing cytostatic 
and cytotoxic effects on cell lines previously resistant to 
TNF-α and IFN-γ individually.
Combinations of TNF-α with IFN-α and IL-2 also 
showed synergistic cytotoxic and cytostatic effects in vitro 
and in vivo. Concomitant TNF-α and IFN-α in a murine 
lung  metastasis  model  significantly  increased  survival 
[31]. TNF-α and IL-2 in murine models with leukemia, 
mastocytoma,  melanoma,  lymphoma  and  sarcoma  cell 
lines also demonstrate combinatorial effects and systemic 
immunological memory [32, 33]. 
The combination of TNF-α and radiotherapy has been Oncotarget 2011; 2:  739 - 751 741 www.impactjournals.com/oncotarget
Table 1: Phase I studies with single agent rhTNF-α
Study
Total 
number of 
patients
Tumor 
Type Dose TNF-α
a Schedule ORR
b MTD Dose Limiting 
Toxcities
Chapman 1987 [35] 13
Advanced 
cancer
1 - 200 µg/m
2
for (IV bolus) 
and 5 - 250 
µg/m
2 (SQ)
Twice  weekly alternating 
SQ/IV rhTNF-α every week for 
4 weeks
8% NR
Hypotension. Local 
tissue reaction. Nausea. 
Vomiting. Neurotoxicity.
Creaven1987 [36] 29
Advanced 
cancer -
solid tumors
1 x 10
4 - 48 x 
10
4 units/m
2 Three doses 3 weeks apart 0%
48 x 10
4
units/m
2 Hypotension.
Kimura 1987 [37] 33
Advanced 
cancer -
solid tumors
1 x 10
5 - 16 
x10
5 units/m
2 One dose 0%
5x 10
5 
units/m
2
Hypotension. 
Thrombocytopenia. 
Hepatotoxicity.
Creagan 1988 [38] 27
Advanced 
cancer -
solid tumors
5 - 200 
µg/m
2/day
Daily for 5 consecutive days 
every 2-3 weeks 
4% 150 µg/m
2  Hypotension. Rigors. 
Phlebitis.
Feinberg 1988 [39] 39
Metastatic 
cancer
5 - 250 
µg/m
2/day 
Daily for five consecutive days 
every two weeks for 8 weeks.  
30 minute vs. 4 hour infusion
0% 200 µg/m
2/day
Hypotension. Nausea. 
Vomiting. Myalgias. 
Fatigue.
Sherman 1988 [40] 19
Advanced 
cancer -
solid tumors
0.5 x 10
4 - 3.0 
x 10
5
units/m
2/day
5-day continuous infusion 
every 4 weeks
0%
3.0 x 10
5 
units/m
2/d.
Thrombocytopenia. 
Leukopenia.
Spriggs 1988 [41] 50
Advanced 
cancer
4.5 - 645 µg/m
2 Continuous infusion over 24 
hours every 3 weeks
2% 636 µg/m
2 Hypotension.
Taguchi 1988 [42] 53
c Malignant 
tumors
0.1 x 10
6 - 5 x 
10
6units/dose 
(IV); 0.1 x 10
6 -
2 x 
10
6units/dose 
(IT)
One dose for week 1, then 
three times a week for week 
2-7
5%
1 x 10
6
units/dose
d Hypotension.
Creaven1989 [43] 33
Advanced 
cancer
5 - 80 x 10
4 
units/m
2/day
Daily for 5 consecutive days 6%
60 x 10
4
units/m
2/day
Hypotension. 
Hepatotoxicity.
Jakubowski1989 
[44]
19
Advanced 
cancer
5 - 200 
µg/m
2/day (IM)
Daily for 5 consecutive days 
every 2 weeks 
0% 150 µg/m
2/day 
Local injection site 
reaction. Leukopenia. 
Thrombocytopenia. 
Hepatoxicity. 
Neurotoxicity.
Wiedenmann1989 
[45] 
15
Advanced 
cancer -
adenocarcin
oma
40 - 400 µg/m
2
Continuous infusion over 24 
hours once or twice weekly for 
8 weeks
0% 200 µg/m
2
Thrombocytopenia. 
Fever. Cholls. Fatigue. 
Myalgia.
Gamm 1991 [46] 62
Advanced 
cancer
2.5 - 200 µg/m
2
Twice  daily for 5 consecutive 
days every two weeks for 8 
weeks
6%
150 
µg/m
2/dose
Hypotension. 
Hepatotoxicity.
Krigel 1991 [47] 27
Advanced 
cancer -
solid tumors
8.5 - 1000 
µg/m
2
100% dose on day 1, then 
20% of initial dose on day 8 -
day 12 repeated every 2 
weeks
0%
267 µg/m
2
(initial dose) 
and 160 µg/m
2 
(subsequent 
daily dosing)
Hypotension. 
Hemorrhagic gastritis.
Logan 1991 [48] 24
Advanced 
cancer -
solid tumors
40 - 240 µg/m
2
100% dose on day 1, then 
daily dosing on day 8 - day 12 
repeated every 3 weeks
NR NR NR
Schiller 1991 [49] 53
Advanced 
cancer
5 - 275 µg/m
2 Three  times a week for 4 
weeks
2% 225 µg/m
2 Hypotension. Fatigue. 
Nausea.
Mittelman1992 [50] 19
Advanced 
cancer -
solid tumors
40 - 200 µg/m
2
24-hour  infusion on day 1 
followed by 120-hour infusion 
day 8 - day 12 repeated every 
3 weeks
0% 160 µg/m
2 Hematologic toxicity. 
Neurotoxicity.
Furman 1993 [51] 27
Pediatric 
advanced 
cancer
100 - 350 
µg/m
2/day
Daily for 5 consecutive days 
every two weeks
4% 300 µg/m
2/day
Cardiotoxicity. 
Hypotension. 
Hepatotoxicity.
Braczkowski1998 
[52]
21
Advanced 
cancer -
solid tumors
75 - 150 µg/day
Daily for 5 consecutive days 
every two weeks
48% N/A NR
a
Al l Studies used intravenous infusion for delivery of TNF-α. unless otherwise indicated.  
b
Ojective response rate calculated using number of 
patients evaluable for response where available. 
c
Intravenous (43 patients) and intratumoral (10 patients). 
d
IVdose only. TNF-α - tumor necrosis 
factor alpha. ORR - objective response rate.  MTD - maxium tolerated dose.  IV - intravenous. IM - intramuscular. SQ - subcutaneous. IT -
intratumoral.Oncotarget 2011; 2:  739 - 751 742 www.impactjournals.com/oncotarget
less extensively studied. Investigation of the interaction 
of TNF-α and radiation in 14 human tumor cells lines 
demonstrated  synergistic  or  additive  cytotoxicity  with 
the maximum effect when TNF-α was given 4-12 hours 
before irradiation [34]. The mechanism of this synergism 
is thought to be due to the induction of oxygen free radical 
species and resulting DNA damage.
clInIcAl trIAls of systemIc 
recombInAnt humAn tnf-α
Systemic rhTNF-α as a single agent
Numerous phase I and phase II studies have been 
conducted to ascertain the toxicity profile and efficacy of 
systemic TNF-α. Studies have encompassed a wide range 
of tumor types in both adult and pediatric patients. In 
the majority of phase I and phase II studies, TNF-α was 
administered as an intravenous bolus injection or infusion. 
However, a few phase I studies have evaluated TNF-α 
with subcutaneous or intramuscular administration. 
 Phase I studies conducted with TNF-α are detailed 
in  table 1 [35-52].  Eighteen  phase  I  studies  were 
conducted  and  published  with  rhTNF-α  as  a  single 
agent  systemic  therapy,  enrolling  between  19  and  62 
patients per study. Study design varied with single dose 
of rhTNF-α, multiple dosing (daily to every three weeks) 
and continuous infusion (one to five day duration) being 
tested. Overall, it appears that a systemic TNF-α dose of 
150-200 µg/m2, given as a 30 minute intravenous infusion 
was identified as MTD in several studies. Dose-limiting 
toxicities (DLT) as well as other side effects that were 
observed seemed to have been universal and in most cases 
reasonably well tolerated and reversible. Common DLTs 
included:  hypotension,  thrombocytopenia,  leukopenia, 
neurotoxicity, fever, nausea/vomiting, as well as general 
symptoms  of  malaise  and  weakness  (table 2).  Other 
pathological sequelae of a transient hypovolemic episode, 
including  transient  elevation  of  liver  enzymes,  were 
reported.  Tumor  responses  however,  when  used  as  a 
single agent, even with more intense treatment schedules, 
were rare. 
Phase  II  studies  using  systemically  administered 
rhTNF-α are detailed in table 3 [53-62]. Studies typically 
investigated  advanced/metastatic  cases  of:  colorectal 
cancer,  breast  cancer,  pancreatic  cancer,  malignant 
melanoma  and  renal  cell  carcinoma.  The  majority  of 
studies  involved  a  small  number  of  cases  (16-26),  an 
exception being a phase II study of various malignancies 
that enrolled 147 patients [59]. Study design varied, with 
150-200 µg/m2 given as a 30 minute intravenous infusion 
daily for 3-5 days and repeated every 1-4 weeks being 
commonly  employed.  In  all  studies,  tumor  responses 
were rare and when they did occur, only partial responses 
were observed. In the largest study of 147 cancer patients 
treated with 150μg/m2 for 5 days every other week, only 
1  partial  remission  was  noted  while  13%  of  patients 
experienced a grade 4 or greater toxicity. The most serious 
toxicities included respiratory failure and coagulopathies. 
Other,  less  serious  and  more  common  side  effects 
reported include: hypotension (31%), leukopenia (38%), 
thrombocytopenia (13%), fever / chills (69%), headache 
(25%), nausea / vomiting (69%) and hepatopathy (10%). 
However, compared to other phase II studies this regimen 
was  fairly  dose-dense  which  may  have  increased  the 
significant toxicity observed.
Systemic  rhTNF-α  in  combination  with 
chemotherapeutics
Phase I and II studies that investigated the safety 
Table 2: Side effects of single agent rhTNF-α
Side Effect
Very Common Hypotension
Hepatotoxicity
Common Nausea
Neurotoxicity
Vomiting
Chills
Fatigue
Fever
Leukopenia
Rigors
Thrombocytopenia
Cardiotoxicity
Gastrointestinal toxicity
Myalgia
Anemia
Dyspnea
Hematologic toxicity
Local tissue reaction
Pain
Pulmonary toxicity
Uncommon Anorexia
Arthropathy
Coagulopathy
Constituitive symptoms
Diarrhea
Fever
Hematuria
Hemorrhagic gastritis
Hyperglycemia
Hypertension
Intracranial hemorrhage
Lethargy
Leukocytosis
Lymphopenia
Neuropathy
Phlebitis
Renal toxicity
Tachycardia
Vascular thrombosis
Side effects to systemic r hTNF-α monotherapy
observed as a dose-limiting toxicity or ≥ grade 3 
toxicity in a phase I or phase II study.  Very 
common side effect seen in > 10 studies.  
Common side effect seen in between 2 and 10 
studies.  Uncommon side effect seen in 1 study.Oncotarget 2011; 2:  739 - 751 743 www.impactjournals.com/oncotarget
Table 3: Phase II studies with single agent rhTNF-α
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Table 4: Studies of systemic TNF-α with chemotherapy
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Table 5: Studies of systemic TNF-α with other cytokines
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and  efficacy  of  systemic  rhTNF-α  combined  with 
carmustine [3], actinomycin D [63, 64], carboplatin and 
etoposide [65], dactinomycin [66] and doxorubicin [67] 
have been reported and are detailed in table 4. In all 
trials,  intravenous  rhTNF-α  was  given  concurrently  or 
sequentially to chemotherapeutics on multiple days and 
treatments being repeated for a number of cycles. Dose 
of intravenous rhTNF-α ranged from 88-200μg/m2 and 
was similar to the dose used for rhTNF-α monotherapy. 
In  one  study  of  rhTNF-α  and  BCNU  in  advanced 
melanoma, a response rate of 20% was seen with BCNU 
alone  compared  to  10.5%  with  BCNU  and  rhTNF-α 
[3].  Additionally,  treatment  of  recurrent  or  refractory 
Wilms tumor with dactinomycin and rhTNF-α resulted 
in a 15.8% response rate [66]. However, while patients 
in this study were previously treated with dactinomycin, 
response to therapy was not conclusively due to the action 
of rhTNF-α. Together, trials of rhTNF-α combined with 
chemotherapeutics have failed to prove that the addition 
of rhTNF-α to the treatment regimen improved outcome. 
Systemic rhTNF-α in combination with cytokines
Many studies have combined systemic administration 
of rhTNF-α with other cytokines such as: IFN-γ [68-72], 
IL-2 [73-76] and IFN-α [76], and these are summarized 
in table 5. In general, phase I studies showed a reduction 
in the MTD of rhTNF-α when used in combination with 
other cytokines for patients with advanced solid tumors. 
This was largely due to the overlap in toxicities of these 
cytokines, that is: hypotension, fever, thrombocytopenia, 
acute  renal  failure,  anemia,  cardiac  arrhythmias  and 
pulmonary  edema.  Disappointingly,  few  objective 
responses were reported and none of the combinations 
were tested in larger randomized phase II studies; most 
likely because of the toxicity associated with combined 
therapy and a lack of efficacy seen in the initial studies.
Systemic  rhTNF-α  in  combination  with 
radiotherapy
Three studies that combined rhTNF-α with external 
beam radiation have also been reported [77-79] and they 
are detailed in table 6. The most recent studies combined 
radiotherapy with both rhTNF-α and the chemotherapeutic 
ranimustine for the treatment of malignant astrocytoma 
[79].  In  these  studies  DLTs  were  not  observed  and 
consequently, the maximum tolerated dose of this regimen 
was difficult to ascertain. In addition, no synergy in terms 
of objective response was noted. 
future dIrectIons of systemIc 
tnf-α
Translation  of  systemic  TNF-α  from  research  to 
clinic has been hampered by significant systemic toxicity 
and a lack of efficacy at MTD [43, 46]. Future directions 
for the development of TNF-α therapy rely on amelioration 
of the toxicity seen with systemic therapy and thereby 
increasing direct tumor response through higher TNF-α 
doses. Alternatively, the exploitation of novel mechanisms 
of action may increase efficacy and safety through indirect 
tumor effects.
Polyethylene glycol (PEG) conjugated proteins have 
shown increased retention and decreased immunogenicity 
in vivo [80]. Attempts to conjugate rhTNF-α with PEG 
has  yielded  a  therapeutic  with  decreased  toxicity  and 
increased  efficacy  in  murine  preclinical  models  [81-
84]. Thamm and colleagues conducted a phase I clinical 
trial  of  PEG-rhTNF-α  in  dogs  with  spontaneously 
occurring  tumors  [85].  Comparatively,  Client-owned 
dogs  provide  an  excellent  model  in  which  to  develop 
novel  anticancer  agents.  These  dogs  are  genetically 
diverse, immunocompetent, share our environment and 
have  similar  types  and  size  of  tumors  to  people  [86]. 
Interestingly,  in  this  study  the  MTD  of  PEG-rhTNF-α 
Table 6: Studies of systemic TNF-α with radiation +/- chemotherapy
Study
Total 
number of 
patients
Tumor 
Type Chemotherapy
Study 
Design
Dose TNF-α
a Regimen Cycles ORR
b MTD
Major 
Reported 
Toxicities
c
Hallahan 1995 
[77]
31
Advanced 
cancer N/A Phase I 
TNF-alpha 10-150 
µg/m2; radiation  (150-
300cGy/day; 30-60Gy 
total)
TNF-alpha given 4 
hours prior to 
radiotherapy
N/A 40%
150 
µg/m2 NR
Fukushima 1998 
[78]
23
Malignant 
astrocytomas
and 
glioblastomas
MCNU Pilot Study
TNF-SAM2 80 x 104
U/m2; MCNU 100 
mg/m2 (IV); radiation 
(1.5Gy/day; 54-60Gy 
total)
8 week  cycle. MCNU 
day  1.  TNF-SAM2 
day  3.  TNF-SAM2 
given weekly  for 5 
doses 
4 12% N/A NR
Fukushima 2003 
[79]
26
Malignant 
astrocytomas 
and 
glioblastomas
MCNU Pilot Study
TNF-SAM2 80 x 104
U/m2; MCNU 100 
mg/m2 (IV); radiation 
(1.5Gy/day; 54-60Gy 
total)
8-12 week  cycle. 
MCNU day 1.  TNF-
SAM2 day 3.  TNF-
SAM2 given weekly 
for 5 doses
4 17% N/A NR
a All  Studies used intravenous infusion for delivery  of TNF-α. 
b Ojective response  rate calculated  using number of patients evaluable  for response where  available.
c Grade 3 or 
greater toxicities.  TNF-α - tumor necrosis  factor alpha.  ORR - objective response  rate.  NR - not reported in study.   N/A - not applicable  for study design.  MCNU - ranimustine.Oncotarget 2011; 2:  739 - 751 747 www.impactjournals.com/oncotarget
was found to be 26.7μg/kg (approximately 815μg/m2) and 
4 of 15 dogs treated had a partial tumor response. DLT 
was similar to that observed with unconjugated TNF-α, 
with hypotension and coagulopathy being observed. This 
study suggests that PEG-rhTNF-α may limit some of the 
undesirable toxicity seen with unconjugated TNF-α and 
allow for greater antitumor responses. 
Asparagine-glycine-arginine  conjugated  to  the 
N-terminus  of  TNF-α  (NGR-TNF-α)  specifically  binds 
the aminopeptidase N (CD13) of tumor vasculature [87]. 
CD13  is  required  for  the  pathological  development  of 
vasculature  in  the  disease  and  presents  an  ideal  target 
to  modulate  the  effect  of  chemotherapeutics  [88,  89]. 
Preclinical  studies  of  NGR-TNF-α  showed  synergism 
with doxorubicin, cisplatin, placitaxel and gemcitabine, 
increasing  tumor  penetration  of  cytotoxic  compounds, 
anticancer efficacy and decreasing treatment associated 
toxicity [90]. Interestingly, increase in efficacy was seen 
in vivo but not in vitro with tumor cell lines, indicating 
that this synergism is due to an indirect effect of NGR-
TNF-α on host vasculature [90]. A recent Phase Ib study 
of low-dose NGR-TNF-α with doxorubicin in advanced 
solid tumors demonstrated that this combination is well 
tolerated with no DLT observed [67]. A phase II dose of 
0.8μg/m2 of NGR-TNF-α and 75mg/m2 of doxorubicin 
was recommended. The study provided hope for future 
development  of  TNF-α  and  doxorubicin  combination 
therapy with 1 of 15 patients achieving a partial response 
and 10 of 15 patients with stable disease for a median 
duration of nearly 6 months.
An alternative concept for the use of TNF-α in the 
treatment  of  human  cancers  exists.  Preclinical  in vivo 
studies  demonstrated  that  the  uptake  of  radiolabeled 
liposomes in tumors was increased by approximately 6 
fold in mice that were concomitantly treated with TNF-α 
[4]. The mechanism behind this enrichment is thought to 
be mediated through effects on the tumor vasculature and 
an enhanced-enhanced permeability and retention (E2PR) 
effect.  In vivo  experiments  using  the  combination  of 
TNF-α and liposomal doxorubicin showed a significantly 
increased survival benefit in tumor-bearing mice treated 
with the combination in comparison to mice treated with 
either TNF-α or liposomal doxorubicin alone. Although 
single-agent  liposomal  doxorubicin  alone  delayed 
tumor growth and led to improved survival, the tumors 
eventually grew back, whereas the combination treatment 
with TNF-α and liposomal doxorubicin led to a long-term 
survival in 80% of the treated animals. These findings are 
in  accordance  with  previously  published  data  showing 
improved  treatment  outcomes  in  rat  osteosarcoma  and 
murine melanoma tumor models that were treated with low-
dose TNF-α plus liposomal doxorubicin in comparison to 
TNF-α plus free doxorubicin [5, 91]. The development of 
low-dose TNF-α and liposomal doxorubicin may provide 
unique synergy to increase efficacy and decrease toxicity 
of combination therapy. Clinical studies are necessary to 
establish the safety and efficacy of this approach. These 
studies are worthwhile considering the novel mechanism 
of synergism between TNF-α and liposomal doxorubicin.
conclusIon
TNF-α has been proven an effective anticancer agent 
in in vitro and in vivo preclinical studies. Sadly, the promise 
of systemic TNF-α has, as of yet, not translated to a patient 
therapy and enthusiasm has been curbed due to the toxicity 
profile and lack of efficacy at MTD. Combination with 
chemotherapy in the setting of hyperthermic isolated limb 
perfusion has proven quite successful, based not only on a 
direct anti-proliferative effect of TNF-α, but also due to its 
ability to increase drug penetration into tumor tissue. The 
future development of systemic TNF-α as an anticancer 
treatment will rely on exploring ways to reduced systemic 
toxicity and exploit novel mechanisms of action to deliver 
greater efficacy simultaneously with decreased toxicity. A 
number of avenues are currently being explored based on 
promising preclinical and early clinical data. The novel 
concept of using systemic TNF-α to facilitate increased 
tumor  penetration  of  liposomal  chemotherapy  seems 
particularly promising and worth exploring clinically. 
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